KNSA
Kiniksa Pharmaceuticals, Ltd.
NASDAQ · BMHealthcareBiotechnology
$62.58-2.14%
Price as of Jul 20, 2026
KNSA valuation
Kiniksa Pharmaceuticals, Ltd. valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- 45.89x
- P/E 2026E
- 49.36x
- P/E 2027E
- 33.95x
- P/E 2028E
- 27.43x
- P/S forward
- 5.20x
Trailing multiples
- P/E TTM
- 63.86x
- PEG TTM
- 1.65x
- Price / book
- 7.95x
- Price / sales
- 6.39x
- Price / cash flow
- 29.03x
Enterprise value
- Enterprise value
- $4.4B
- EV / sales
- 5.78x
- EV / EBITDA
- 40.46x
- EV / EBIT
- 46.73x
- Market cap
- $4.8B
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.